National Drug Control Policy Office – Federal Register Recent Federal Regulation Documents
Results 51 - 100 of 102
Paperwork Reduction Act; Proposed Collection; Comment Request
The Office of National Drug Control Policy (ONDCP) intends to submit the following information collection request to the Office of Management and Budget for review and approval under the Paperwork Reduction Act of 1995 (Pub. L. 104-13, 44 U.S.C. Chapter 35).
Removal of 5 Counties as High Intensity Drug Trafficking Areas
The Director of the Office of National Drug Control Policy (ONDCP) removed 5 counties as High Intensity Drug Trafficking Areas (HIDTA) counties pursuant to 21 U.S.C. 1706, effective September 29, 2014. The 5 counties removed from HIDTA county designation within the Appalachia HIDTA are (1) Cumberland and Clinton Counties in Kentucky; (2) Clay and White Counties in Tennessee; and (3) Mason County in West Virginia. The Executive Board of the Appalachia HIDTA requested removal of these counties from designation after assessing the threat and determining that these counties no longer met the statutory criteria necessary for designation as HIDTA counties. ONDCP evaluated and accepted the request.
Notice of HIDTA Designations
The Director of the Office of National Drug Control Policy designated 26 additional counties/cities as High Intensity Drug Trafficking Areas (HIDTA) pursuant to 21 U.S.C. 1706. The new counties/ cities are (1) Madison and Nelson Counties in Kentucky, Tazewell County in Virginia, and Harrison County in West Virginia as part of the Appalachia HIDTA; (2) Pasco County in Florida as part of the Central Florida HIDTA; (3) Trinity and Siskiyou Counties in California as part of the Central Valley California HIDTA; (4) Brazoria County in Texas as part of the Houston HIDTA; (5) Rockingham County in New Hampshire as part of the New England HIDTA; (6) Chautauqua, Dutchess, Putnam, and Rockland Counties in New York as part of the New York/New Jersey HIDTA; (7) Ada and Canyon Counties in Idaho, and Malheur County in Oregon as part of the Oregon HIDTA; (8) Gallatin County in Montana as part of the Rocky Mountain HIDTA; (9) Potter and Randall Counties in Texas as part of the Texoma HIDTA; and (10) Berkeley County in West Virginia and the Cities of Chesapeake, Hampton, Newport News, Norfolk, Portsmouth, and Virginia Beach in Virginia as part of the Washington/Baltimore HIDTA.
Appointment of Members of Senior Executive Service Performance Review Board
The following persons have been appointed to the ONDCP Senior Executive Service Performance Review Board: Dr. Terry Zobeck (as Chair), Mr. Gerard Burns, Ms. Michele Marx, and Mr. Jeffrey Teitz.
Summit on Heroin and Prescription Drugs: Federal, State, and Community Responses
The Office of National Drug Control Policy (ONDCP) will host a ``Summit on Heroin and Prescription Drugs: Federal, State, and Community Responses'' highlighting the public health and safety issues surrounding prescription painkillers and heroin. The conference will be held from 9 a.m. to 12:30 p.m. on Thursday, June 19, 2014 in the South Court Auditorium of the Eisenhower Executive Office Building, 17th Street and Pennsylvania Avenue NW., Washington, DC 20500. While the summit is not open to the general public, it will be streamed live on- line for the general public to view on www.WhiteHouse.gov/Live. The goal of the summit is to discuss trends and challenges in the epidemic of opioid abuse in the United States, identify innovative practices and models, and discuss how practitioners at every level can help reduce overdose deaths and public health consequences. Participants will include Attorney General Eric Holder, Vermont Governor Peter Shumlin, National Institute on Drug Abuse Director Dr. Nora Volkow, and experts from across the country on education, treatment, and overdose and infectious disease prevention. Summit participants will not be deliberating or providing consensus advice or recommendations to ONDCP. Issues explored will include expanding drug treatment access to millions through the Affordable Care Act, encouraging people and medical professionals to learn the signs and symptoms of problematic drug use and to intervene before substance use becomes a chronic condition, and supporting the use of naloxone, an overdose reversal drug that's easy to administer and has already saved thousands of lives.
Designation of Thirteen Counties as High Intensity Drug Trafficking Areas
The Director of the Office of National Drug Control Policy designated thirteen additional counties as High Intensity Drug Trafficking Areas pursuant to 21 U.S.C. 1706. The new counties are (1) Bradley County in Tennessee, Dickenson County in Virginia, and Wyoming and Raleigh Counties in West Virginia as part of the Appalachia HIDTA; (2) Rockingham County in North Carolina, and Florence and Horry Counties in South Carolina as part of the Atlanta-Carolinas HIDTA (formerly known as ``Atlanta HIDTA''); (3) Forrest County in Mississippi as part of the Gulf Coast HIDTA; (4) Williams County in North Dakota as part of the Midwest HIDTA; (5) Humboldt County in California as part of the Northern California HIDTA; and (6) Cecil and Frederick Counties in Maryland and Roanoke County in Virginia as part of the Washington/Baltimore HIDTA.
Technology Innovations for Substance Abuse and Mental Health Treatment Conference & Related Health Information Technology (HIT) Meeting
The Office of National Drug Control Policy (ONDCP) and the Substance Abuse and Mental Health Administration (SAMHSA) in partnership with the Office of the National Coordinator for Health Information Technology, and the National Institutes of Health's Office of Behavioral and Social Sciences Research, will host a Technology Innovations for Substance Abuse and Mental Health Treatment Conference highlighting promising innovations for treating these disorders. This conference will bring together innovators in technology and health care experts promoting the dissemination of innovative, evidence-based technologies that advance prevention, treatment, and recovery for these disorders. The conference will be held on September 16, 2013 from 8:00 a.m. to 5:00 p.m. in the South Court Auditorium, Eisenhower Executive Office Building, 17th Street and Pennsylvania Avenue NW., Washington DC, 20500. The goal of this conference is to highlight advances in health information technologies (HIT) for behavioral health, and promote technology advances and dissemination of evidence-based tools that address patient safety and the advancement of successful prevention, treatment and recovery. The specific conference objectives are to: (1) Promote evidence-based tools to advance treatment of substance use and mental health disorders; (2) advance the Administration's 2010 National Drug Control Strategy blueprint and the HIT initiatives at SAMHSA and the Office of the National Coordinator; and (3) encourage the use of technologies to improve health, improve quality of care, and increase patient engagement. On Tuesday, September 17, SAMHSA and ONDCP are holding a smaller meeting with state representatives and health system administrators on HIT systems to discuss technical issues and obtain experiential and anecdotal information from each of the attendees. This group will not be deliberating or providing consensus advice or recommendations to SAMHSA or ONDCP. The meeting will be held 9:00 a.m. to 1:00 p.m. in the 5th Floor Conference Room of ONDCP at 750 17th Street NW., Washington DC, 20503. Members of the public who wish to attend on either day are required to call ONDCP's Technology Innovations for Substance Abuse and Mental Health Treatment Conference telephone line at (202) 395-5696 to reserve a seat and arrange building access by no later than Monday, September 9, 2013. Seating for members of the public is limited and will be assigned on a first call, first served basis. The September 16 conference will be live-streamed on-line for members of the public who wish to observe, and conference material will be available to the public following the meeting. Go to https://www.whitehouse.gov/ondcp for more information. To Attend or For Further Information Contact: June Sivilli at (202) 395-5696 or email rsvpITSept16@ondcp.eop.gov.
Appointment of Members of Senior Executive Services Performance Review Board
The following persons have been appointed to the ONDCP Senior Executive Service Performance Review Board: Mr. Jeffrey Teitz, Dr. Terry Zobeck, Ms. Martha Gagne, and Mr. Gerard Burns.
Paperwork Reduction Act; Notice of Intent To Collect; Comment Request
ONDCP proposes the extension of three existing data collection instruments used in the production of advertising for the National Youth Anti-Drug Media Campaign and for advertising tracking. Purpose: The existing data collection instruments are critical to the continuity and improvement of the National Youth Anti-Drug Media Campaign. Type and Title of Collections: Qualitative Research, OMB 3201-0011, uses focus groups. Copy Testing, OMB 3201-0006, consists of 15-minute online interviews. Tracking Study, OMB 3201-0010, consists of 15-minute online interviews. Frequency: Qualitative Research and Copy Testing performed quarterly. Tracking Study performed weekly. Affected Public: Teenagers and adult influencers of teenagers. Estimated Burden: Qualitative Research, $19,800; Copy Testing, $16,500; Tracking Study, $37,700. Additional information: Collection instruments similar to those proposed are available at the Information Collection Review section of https://www.reginfo.gov/public/jsp/Utilities/index.jsp. Contact: Address comments or questions to Andrew Hertzberg through any of the following: Executive Office of the President, Office of National Drug Control Policy, Washington DC 20503; AHertzberg@ondcp.eop.gov; (202) 395-6721 (fax); or, (202) 395-6353 (voice).
Appointment of Members of Senior Executive Services Performance Review Board
The following persons have been appointed to the ONDCP Senior Executive Service Performance Review Board: Mr. Jeffery J. Teitz, Ms. Martha Gagne, Mr. Robert W. Denniston, and Ms. Michelle C. Marx.
Revised Meeting Notice: Leadership Meeting on Maternal, Fetal, and Infant Opioid Exposure and Neonatal Abstinence Syndrome
An ONDCP Leadership Meeting on Maternal, Fetal and Infant Opioid Exposure and Neonatal Abstinence Syndrome (NAS) will bring together leaders in the field of policy, opioid exposed infants, pain treatment during pregnancy, and addiction treatment during and after pregnancy. The meeting will be held on Thursday, August 30th 2012 in the Indian Treaty Room, Eisenhower Executive Office Building, 17th Street and Pennsylvania Avenue NW., Washington D.C, 20500 starting at 9:00 a.m. and concluding at 5:30 p.m. The overall objectives of the meeting are to review the state of science and policy and discuss the remaining challenges to the field concerning the upswing in maternal prescription drug abuse and dependence and resulting increases in opioid exposed babies with NAS and possibly other consequences. Misuse and abuse of, and dependence upon, prescription opioid drugs adversely affect the health of millions of Americans and their families. The specific conference objectives are: (1) To share research findings concerning the NAS epidemic and its costs; (2) to begin a national discussion concerning promising and best practices for treating opioid exposed babies; (3) to raise awareness about opioid misuse and dependence during pregnancy and the need for women with drug use disorders to access treatment through family medicine and gynecological practitioners, and specialty treatment providers; (4) to discuss legal and policy issues related to opioid using pregnant women and mothers including barriers to accessing treatment; (5) to promote awareness among regulatory agencies and insurers concerning the risks and benefits of opioids to developing fetuses and the likelihood of neonatal abstinence syndrome resulting from long term opioid use during pregnancy; and (6) to raise awareness about risk prevention opportunities among practitioners and regulators. Members of the public who wish to attend this meeting should telephone ONDCP's Maternal, Fetal, and Infant Opioid Exposure and Neonatal Abstinence Syndrome telephone line at (202) 395-7454 to arrange building access no later than Friday, August 10, 2012. Seating for members of the public is limited and will be assigned on a first come, first served basis. To Attend or For Further Information Contact: Cecelia Spitznas, Ph.D. at (202) 395-7454 or email rsvp@ondcp.eop.gov.
Leadership Meeting on Maternal, Fetal, and Infant Opioid Exposure and Neonatal Abstinence Syndrome
An ONDCP Leadership Meeting on Maternal, Fetal and Infant Opioid Exposure and Neonatal Abstinence Syndrome (NAS) will bring together leaders in the field of policy, opioid exposed infants, pain treatment during pregnancy, and addiction treatment during and after pregnancy. The meeting will be held on Thursday, August 30th 2012 at the White House Conference Center at 726 Jackson Place, NW., Washington D.C., starting at 9:00 a.m. and concluding at 5:30 p.m. The overall objectives of the meeting are to review the state of science and policy and discuss the remaining challenges to the field concerning the upswing in maternal prescription drug abuse and dependence and resulting increases in opioid exposed babies with NAS and possibly other consequences. Misuse and abuse of, and dependence upon, prescription opioid drugs adversely affect the health of millions of Americans and their families. The specific conference objectives are: (1) To share research findings concerning the NAS epidemic and its costs; (2) to begin a national discussion concerning promising and best practices for treating opioid exposed babies; (3) to raise awareness about opioid misuse and dependence during pregnancy and the need for women with drug use disorders to access treatment through family medicine and gynecological practitioners, and specialty treatment providers; (4) to discuss legal and policy issues related to opioid using pregnant women and mothers including barriers to accessing treatment; (5) to promote awareness among regulatory agencies and insurers concerning the risks and benefits of opioids to developing fetuses and the likelihood of neonatal abstinence syndrome resulting from long term opioid use during pregnancy; and (6) to raise awareness about risk prevention opportunities among practitioners and regulators. Members of the public who wish to attend the meeting should telephone ONDCP's Maternal, Fetal, and Infant Opioid Exposure and Neonatal Abstinence Syndrome telephone line at (202) 395-7454 to arrange building access. To Attend or For Further Information Contact: Cecelia Spitznas, Ph.D. at (202) 395-7454 or email rsvp@ondcp.eop.gov.
Paperwork Reduction Act; Proposed Collection; Comment Request
The Office of National Drug Control Policy (ONDCP) intends to submit the following information collection request to the Office of Management and Budget for review and approval under the Paperwork Reduction Act.
Designation of ONDCP SES Performance Review Board Members
The Director of the Office of National Drug Control Policy has appointed Patrick M. Ward, Robert Denniston, Michele Marx, and Jeffrey Teitz as members of the ONDCP SES Performance Review Board (PRB).
Draft Tribal Consultation Policy
Pursuant to Executive Order 13175, the Director, National Drug Control Policy, is establishing a policy governing how the Office of National Drug Control Policy, Executive Office of the President [ONDCP] will consult with American Indian and Alaska Native Tribes, tribal organizations and urban Indian organizations regarding Federal policies that directly affect Indian Country and urban Indian communities.
Appointment of Members of Senior Executive Services Performance Review Board.
The following persons have been appointed to the ONDCP Senior Executive Service Performance Review Board: Dr. Terry Zobeck, Ms. Martha Gagne, Ms. Christine Leonard, and Mr. Patrick Ward.
Designation of Nine Counties as High Intensity Drug Trafficking Areas
The Director of the Office of National Drug Control Policy designated nine additional counties as High Drug Trafficking Areas pursuant to 21 U.S.C. 1706. The new counties are (1) Shelby County in Tennessee as part of the Gulf Coast HIDTA, (2) Navajo County in Arizona as part of the Southwest Border HIDTAArizona Region, (3) Jefferson County in New York as part of the New York/New Jersey HIDTA, (4) Mecklenburg, Gaston, Union Buncombe, Henderson, and McDowell Counties in North Carolina as part of the Atlanta HIDTA.
Designation of Five Counties as High Intensity Drug Trafficking Areas
The Director of the Office of National Drug Control Policy designated five additional counties as High Drug Trafficking Areas pursuant to 21 U.S.C. 1706. The new counties are (1) Rock and Brown Counties in Wisconsin as additions to the Milwaukee HIDTA, (2) Lane County and Warm Springs Indian Reservation in Oregon as additions to the Oregon HIDTA, and (3) Travis County, Texas as an addition to the Southwest Border HIDTA, South Texas Region.
Paperwork Reduction Act; Proposed Collection; Comment Request
The Office of National Drug Control Policy (ONDCP) intends to submit the following information collection request to the Office of Management and Budget for review and approval. ONDCP seeks public comment.
Appointment of Members of Senior Executive Services Performance Review Board
The following persons have been appointed to the ONDCP Senior Executive Service Performance Review Board: Dr. Terry Zobeck, Ms. Michele Marx, Mr. Robert Denniston, and Ms. Martha Gagne.
Appointment of Members of Senior Executive Services Performance Review Board
The following persons have been appointed to the ONDCP Senior Executive Service Performance Review Board: Dr. Terry Zobeck, Mr. Mark Coomer, Mr. Robert Denniston, and Ms. Martha Gagne.
Paperwork Reduction Act; Notice of Intent To Collect; Comment Request; Summary of Comments
ONDCP invites comments on a collection of information.
Paperwork Reduction Act; Notice of Intent To Collect; Comment Request
This action proposes the renewal of three existing data collection instruments used in the production of ONDCP's National Youth Anti-Drug Media Campaign advertising and Media Campaign tracking.
Paperwork Reduction Act; 30-Day Notice
In accordance with the Paperwork Reduction Act of 1980, as amended (44 U.S.C. 3501 et seq.), the Office of National Drug Control Policy (ONDCP) announces that it will submit to the Office of Management and Budget (OMB) Office of Information and Regulatory Affairs (OIRA) an information collection request for processing under 5 CFR 1320.10.
Appointment of Members of Senior Executive Services Performance Review Board
The following persons have been appointed to the ONDCP Senior Executive Service Performance Review Board: Mr. Thomas Riley, Ms. Michele Marx, Mr. Robert Denniston, and Mr. Patrick Ward.
Drug-Free Communities Support Program National Evaluation and STOP Act Program National Evaluation; Proposed Information Collection; Notice of 60-Day Public Comment Period
In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Executive Office of the President, Office of National Drug Control Policy, Drug Free Communities (DFC) Support Program is publishing the following summary of proposed information collections for public comment. This notice also includes a summary of proposed information collection for the Substance Abuse and Mental Health Services Administration Sober Truth on Preventing Underage Drinking (STOP Act) Program, which will fund current and past DFC grantees. The STOP program will be evaluated based on the same data already being collected for the ONDCP DFC program. No additional data will be required of respondents. Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the programs' functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden. Executive Office of the President, Office of National Drug Control Policy is requesting OMB review and approval of this information collection. Written comments and/or recommendations will be accepted from the public if received by the individuals designated below within 60 days from the date of publication. Type of Information Collection Request: New collection. Title: Drug-Free Communities (DFC) Support Program National Evaluation; Sober Truth on Preventing Underage Drinking (STOP Act) Program National Evaluation. Use: 1. The DFC Support Program is an integral component of the National Drug Control Strategy and a requirement of Healthy People 2010. The DFC has two primary goals: (1) Reduce substance abuse among youth by addressing local risk and protective factors to minimize the likelihood of subsequent substance abuse in the community; and (2) support community anti-drug coalitions in becoming self-sufficient by establishing, strengthening, and fostering collaboration among public and private nonprofit agencies, as well as federal, state, local, and tribal governments to prevent and reduce substance abuse. A National Evaluation of the DFC Support Program commenced in September 2004 to assess the program's implementation and effectiveness. The major purpose of the DFC Support Program National Evaluation is to design and implement a rigorous evaluation and to support an effective grant monitoring and tracking system. The National Evaluation will make use of two separate collection instruments to gather information. The Monitoring and Tracking Questionnaire (online tool) will serve as a semi-annual report for DFC grantees and will provide information for ONDCP, SAMHSA and the National Evaluation. The Typology Classification Questionnaire will be used on an annual basis to classify respondents into a coalition typology developed by the evaluation contractor and will provide information for ONDCP and the National Evaluation. Frequency: Semi-annually and annually. Affected Public: Anti-Drug Coalitions. Type of Respondents: Directors of Anti-Drug Coalitions or their designees. 2. The purpose of the STOP Act program is to prevent and reduce alcohol use among youth in communities throughout the United States. It was created to strengthen collaboration among communities, the Federal Government, and State, local and tribal governments; to enhance intergovernmental cooperation and coordination on the issue of alcohol use among youth; to serve as a catalyst for increased citizen participation and greater collaboration among all sectors and organizations of a community that first demonstrates a long-term commitment to reducing alcohol use among youth; and to disseminate to communities timely information regarding state-of-the-art practices and initiatives that have proven to be effective in preventing and reducing alcohol use among youth. The statutory authority for this program limits eligibility to domestic public and private nonprofit entities that are currently grantee organizations receiving or having received grant funds under the Drug-Free Communities Program (DFC). STOP Act grants are authorized under the Public Health Service (PHS) Act (42 U.S.C. 290bb-25b), Section 519B. The National Evaluation will make use of one collection instrument to gather information. The Monitoring and Tracking Questionnaire (online tool) will serve as a semi-annual report for STOP Act grantees and will provide information for SAMHSA. Frequency: Semi-annually. Affected Public: Current or prior Drug Free Communities Anti-Drug Coalitions. Type of Respondents: Directors or their designees. Estimated annual burden is as follows:
Designation of Twenty-six Counties as High Intensity Drug Trafficking Areas
This notice lists twenty-six counties designated as additions to the High Intensity Drug Trafficking Areas (HIDTA) Program by the Director of the Office of National Drug Control Policy (ONDCP). These new counties are: Letcher County in Kentucky and Hamilton and Washington Counties in Tennessee as additions to the Appalachia HIDTA; Barrow, Bartow, Cherokee, Clayton, Douglas, Fayette, Forsyth and Henry Counties in Georgia and Durham, Johnston, Wake, Wayne and Wilson Counties in North Carolina as additions to the Atlanta HIDTA; Shasta County, California as an addition to the Central Valley California HIDTA; Benton, Jefferson, Pulaski and Washington Counties in Arkansas as additions to the Gulf Coast HIDTA; Rock Island County, Illinois as an addition to the Midwest HIDTA; Chester and Delaware Counties in Pennsylvania as additions to the Philadelphia/Camden HIDTA; and Midland and Ector Counties in Texas as additions to the Southwest Border HIDTA West Texas Region. The new counties are designated pursuant to Office of National Drug Control Policy Reauthorization Act of 2006 codified at 21 USCS 1706 et seq, to promote more effective coordination of drug control efforts. In considering whether to designate an area under this section as a High Intensity Drug Trafficking Area, the Director considered, in addition to such other criteria the Director, ONDCP considers to be appropriate, the extent to which: (1) The area is a significant center of illegal drug production, manufacturing, importation, or distribution; (2) state and local law enforcement agencies have committed resources to respond to the drug trafficking problem in the area, thereby indicating a determination to respond aggressively to the problem; (3) drug-related activities in the area are having a significant harmful impact in the area, and in other areas of the country; and (4) a significant increase in allocation of Federal resources is necessary to respond adequately to drug-related activities in the area. This action will support local, state and Federal law enforcement officers in assessing regional drug threats, designing strategies to combat the threats, developing initiatives to implement the strategies, and evaluating the effectiveness of their coordinated efforts.
Paperwork Reduction Act; Notice of Intent to Collect; Comment Request
This action proposes the collection of drug control information from state Medicaid directors.
Paperwork Reduction Act; Notice of Intent To Collect; Comment Request
This action proposes the collection of drug control information from State Educational Agencies regarding State and local support for the Student Drug Testing Programs.
Paperwork Reduction Act; Notice of Intent To Collect; Comment Request
This action proposes the collection of drug control information from State Educational Agencies regarding State and local support for the Student Drug Testing Programs.
Paperwork Reduction Act; Notice of Intent To Collect; Comment Request
This action proposes the collection of drug control information from federal, state, and local governments.
Leadership Conference on Medical Education in Substance Abuse
A conference of leaders in the field of medical education and healthcare policy will be held on Wednesday, January 16th, 2008 at the Hyatt Regency Hotel, Washington, DC on Capitol Hill, New Jersey Ave., NW., and Washington DC, starting at 8 a.m. and concluding at 5:30 p.m. The overall objectives of the Leadership Conference are to advance widespread use of screening and brief intervention procedures designed to identify and promote behavioral change in populations engaged in risky, problematic substance use, or that have a diagnosis of abuse/ addiction. Abuse of illicit drugs, alcohol, or prescription drugs adversely affects the health of millions of Americans. Wide-spread implementation of screening and brief intervention procedures can have a major, positive impact on public health. The specific conference objectives are: (1) To share with medical educators and other contributors to improving in public health, the positive benefits of screening and brief interventions; (2) To devise strategies to implement and sustain Screening, Brief Intervention and Referral to Treatment (SBIRT) procedures for substance abuse in various healthcare settings; (3) To promote adoption and use of new reimbursable healthcare procedural codes (screening and brief intervention) and examine cost-effectiveness of implementing the codes; (4) To address best practices for performing these procedures in various healthcare settings; (5) To identify challenges to implementation of these procedures in various healthcare settings and conceptualize strategies to address these challenges; (6) To generate business models for the procedures applicable to specific heath care environments; (7) To address training and educational needs for the medical community and devise efficient methods for widespread dissemination of these practices. Members of the public who wish to attend the meeting should telephone ONDCP's Leadership Conference on Medical Education telephone line at (202) 395-6750 to arrange building access.
High Intensity Drug Trafficking Areas; Petitions for Designation
Pursuant to the Office of National Drug Control Policy Reauthorization Act of 2006, Public Law 109-469, section 707(c), the Director, National Drug Control Policy is establishing regulations under which interested coalitions of law enforcement agencies from an area may petition for designation as a high intensity drug trafficking area. Public Comment: On June 4, 2007 (Volume 72, Number 106, Notices Page 30862-30864), the Executive Office of the President, Office of National Drug Control published Notice of its intent to issue this regulation. A 60-day public comment period was established. The June 4 Notice stated that any written comments must be received by ONDCP via electronic mail or facsimile on or before August 3, 2007. In addition, an ONDCP staff point of contact was listed to provide additional information as appropriate. ONDCP did not receive any comments. Therefore, ONDCP is issuing this Notice of the agency's intent to publish a regulation identical to the document published on June 4, 2007.
High Intensity Drug Trafficking Areas; Petitions for Designation
Pursuant to the Office of National Drug Control Policy Reauthorization Act of 2006, Public Law 109-469, section 707(c), the Director, National Drug Control Policy is establishing regulations under which interested coalitions of law enforcement agencies from an area may petition for designation as a high intensity drug trafficking area.
Meeting of the Advisory Commission on Drug Free Communities
In accordance with the Drug-Free Communities Act, a meeting of the Advisory Commission on Drug Free Communities will be held on June 27 and 28, 2007 at the Office of National Drug Control Policy in the 5th Floor Conference Room, 750 17th Street, NW., Washington, DC. The meeting will commence at 8:30 a.m. on Wednesday, June 27th, 2007 and adjourn for the evening at 5 p.m. The meeting will reconvene at 8:30 a.m. on Thursday, June 28th, 2007 in the same location. The meeting will adjourn at 4 p.m. on Thursday, June 28th, 2007. The agenda is slated to include: Remarks by ONDCP Director John P. Walters, remarks by the DFC Program's Administrator, Jack Claypoole, and remarks by Policy Analyst Ken Shapiro. There will also be a discussion of the program's evaluation, a discussion about the reauthorization of the Drug Free Communities Program, a review of the new grant process, and an update from the Substance Abuse and Mental Health Services Administration. There will be an opportunity for public comment from 9- 9:30 on Thursday, June 28th, 2007. Members of the public who wish to attend the meeting and/or make public comment should contact ShaNice Stokes, at (202) 395-6699 to arrange building access.
Paperwork Reduction Act; Proposed Collection; Comment Request
The Office of National Drug Control Policy (ONDCP) intends to submit the following information collection request to the Office of Management and Budget for review and approval. ONDCP seeks public comment. Abstract: ONDCP will conduct face-to-face interviews and acquire urine samples from booked arrestees to obtain information concerning drug use; drug and alcohol treatment; and, drug market participation and arrests. The use and manufacture of methamphetamines are of particular interest. Participation is voluntary. Type of Information Collection: New collection. Title: Arrestee Drug Abuse Monitoring (ADAM II) Program Questionnaire. Affected Public: Persons arrested and booked in one of 10 pre- selected booking facilities in the United States in one of two, 2-week data collection cycles spanning six months. Estimated Burden: ADAM II proposes 10 sites that each conduct two cycles of surveys from 250 arrestees per cycle. The total number of participants is 5000. The average survey estimate is 20 minutes. Total burden estimate is 1667 hours. Goals: ONDCP intends to obtain drug-use data that is directly comparable to data collected under the 2000-2003 National Institute of Justice sponsored Arrestee Drug Abuse Monitoring program; provide consistent data collection points to support statistical trend analysis for the use of heroin, cocaine, crack, marijuana and methamphetamine; monitor the spread or emergence of methamphetamine use; and, support ONDCP's efforts to estimate chronic drug use and examine drug market behaviors. Comment Request: Public comments should address whether the proposed data is proper for the functions of the agency; whether the information will have practical utility; the accuracy of ONDCP's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions; the quality, utility, and clarity of the information to be collected; and, the burden on proposed respondents, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, such as electronic submission of responses. Comments will be accepted for sixty days.
Meeting of the Advisory Commission on Drug Free Communities
In accordance with the Drug Free Communities Act, a meeting of the Advisory Commission on Drug Free Communities will be held on December 7 and 8, 2006, at the Office of National Drug Control Policy in the 5th Floor Conference Room, 750 17th Street NW., Washington, DC. The meeting will commence at 8:30 a.m. on Thursday, December 7, 2006 and adjourn for the evening at 5:30 p.m. The meeting will reconvene at 8:30 a.m. on Friday, December 8, 2006 in the same location. The meeting will adjourn at 4 p.m. on Friday, December 8, 2006. The agenda includes: Remarks by ONDCP Director John P. Walters, remarks by ONDCP Deputy Director Mary Ann Solberg, remarks by the DFC Program's Administrator, a discussion of the program's evaluation, a review of new grant awards, and an update from the Substance Abuse and Mental Health Services Administration. There will be an opportunity for public comment from 9-9:30 on Friday December 8, 2006. Members of the public who wish to attend the meeting and/or make public comment should contact Carlos Dublin, at (202) 395-6762 to arrange building access.
Leadership Conference on Medical Education in Substance Abuse, November 30-December 1, 2006
A conference of leaders in the field of medical education in substance abuse will be held on Thursday, November 30 and Friday, December 1, 2006, at the Westin Embassy Row Hotel, Massachusetts Avenue, NW., Washington, DC. The conference will begin at 6 p.m. on Thursday, November 30 and conclude at 5:30 p.m. on Friday, December 1. The specific objectives of the Leadership Conference are: (1) To enhance awareness of the contribution substance abuse screening and brief intervention programs can make to public health in the United States; (2) To identify best practices to cope with emerging patterns of drug- specific abuse; (3) To receive reports on improvements in medical education in drug and alcohol-related disorders; and (4) To encourage the development of medical education curricula on alcohol and other drug related disorders. Members of the public who wish to attend the meeting should telephone ONDCP's Leadership Conference on Medical Education telephone line at (202) 395-6750 to arrange building access.
Appointment of Members of Senior Executive Services Performance Review Board
The following persons have been appointed to the ONDCP Senior Executive Service Performance Review Board: Ms. Michele Marx, Mr. Joseph Keefe, Mr. Robert Denniston, and Mr. Patrick Ward.
Meeting of the Advisory Commission on Drug Free Communities
In accordance with the Drug-Free Communities Act, a meeting of the Advisory Commission on Drug Free Communities will be held on September 28 & 29, 2005, at the Office of National Drug Control Policy in the 5th Floor Conference Room, 750 17th Street NW., Washington, DC. The meeting will commence at 12 noon on Wednesday, September 28, 2005 and adjourn for the evening at 5:30 p.m. The meeting will reconvene at 8:30 a.m. on Thursday, September 29 in the same location. The meeting will adjourn at 4 p.m. on Thursday, September 29. The agenda will include: Remarks by ONDCP Deputy Director Mary Ann Solberg, remarks by the DFC Program's Acting Administrator, a discussion of the program's evaluation, a review of the new grant awards, and an update from the Substance Abuse and Mental Health Services Administration. There will be an opportunity for public comment from 9-9:30 on Thursday September 29. Members of the public who wish to attend the meeting and/or make public comment should contact Carlos Dublin, at (202) 395-6762 to arrange building access.
Paperwork Reduction Act; Comment Request
The Office of National Drug Control Policy (ONDCP) provides this opportunity for public comment on three data collection projects proposed by the National Youth Anti-Drug Media Campaign. The proposed projects are similar to existing projects but stem from the hiring of a new advertising contractor. We propose the following: (1) Qualitative testing of creative concepts; (2) advertising testing before inclusion into the media plan; and, (3) a tracking study to measure advertising effectiveness. Comments must be received within 60 days of this publication.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.